LinkedInXFacebook
Subscribe
Orthopedics This Week
  • My Feed
  • |Posts
  • |Events
  • |MSK Innovations
  • |Power Rankings
  • |Masterclasses
  • |Technology Awards
  • Press Releases
  • |Advertising
  • |Job Board
  • Spine
  • ◆Joints
  • ◆Upper Extremities
  • ◆Foot & Ankle
  • ◆Sports Medicine
  • ◆Pain Mgmt
  • ◆Trauma
  • ◆Biologics
  • ◆Technology
  • ◆People
  • ◆Company News
  • ◆Legal & Regulatory
Home/Biologics/Glass Bone Putty Gains Clearance
Biologics

Glass Bone Putty Gains Clearance

July 8, 2013 1 min read Premium comments

Advertisement

Glass Bone Putty Gains Clearance
Glass Bone Putty / Courtesy of Synergy Biomedical, LLC
Secondary

Bone putty made of spherical glass particles has received FDA clearance, according to its manufacturer, Synergy Biomedical, LLC, and is launching its first bone graft product called BioSphere Putty. Company officials claim that BioSphere, which uses a specialized form of 45S5 bioactive glass with a unique sphere shape, provides an optimized bone graft material that outperforms other bioactive products.

Among claims for the product is that the spherical shape of the BioSphere particles provides uniform and repeatable resorption and ion release. The 3-D packing of the spheres in a bone defect creates an optimal porosity that allows bone formation throughout the implant. Biosphere Putty is composed of bioactive glass spheres that are combined with a moldable phospholipid carrier. Company officials say that the putty has the highest bioactive glass composition on the market.

“The use of spherical particles has allowed Synergy to identify an optimal form of bioactive glass that improves bone formation, ” stated Mark Borden, Ph.D., CEO and founder of Synergy Biomedical. Established in 2011, Synergy Biomedical is a privately held medical device company focused on bringing biomaterial based products to the orthopedic and spinal markets.

React:

Discussion

14
DS
Dr. Sarah MitchellOrthopedic Surgeon · Mayo Clinic

This is a fascinating development. In my practice we've seen similar outcomes with the revised protocol. The key differentiator seems to be patient selection criteria. Has anyone else noticed the correlation with BMI thresholds?

8
JT
James Thornton, MDSpine Fellow · HSS

Great point. I'd push back slightly on the conclusion, the sample size in the cited study is too small to draw population-level inferences. That said, the directional signal is compelling and worth a larger RCT.

5
RP
R. PatelSports Medicine · Stanford

We implemented a similar approach last year. Early results are promising but we're still gathering 12-month follow-up data. Happy to share our protocol if anyone is interested.

Join the conversation

Orthopedic professionals are discussing this. Sign in and upgrade to read every comment and add your voice.

Subscribe

Get Full Access

Read every OTW article and join member discussions for $24.99/month.

Get Full Access

Advertisement

Advertisement

Advertisement

Orthopedics This Week

The most trusted source in orthopedic industry news since 2005. Covering spine, joints, trauma, biologics, and the business of orthopedics.

A publication of RRY Publications, LLC

LinkedInXFacebook

Categories

  • Spine
  • Joints
  • Upper Extremities
  • Foot & Ankle
  • Sports Medicine
  • Pain Mgmt
  • Trauma
  • Biologics
  • Technology
  • People
  • Company News
  • Legal & Regulatory

Resources

  • Subscribe
  • Community Posts
  • Job Board
  • Press Release Opportunities
  • Power Rankings
  • About OTW
  • Advertise
  • Contact Us

Get Full Access

Unlimited articles, community posts, and Power Rankings.

Get Full Access

Plans start at $24.99/mo · Annual saves 20%

© 2026 Orthopedics This Week · RRY Publications, LLC

Privacy PolicyTerms of ServiceCookie Policy